Welcome to YLOAN.COM
yloan.com » Health » Pipeline And Commercial Insight: Schizophrenia - Opportunity Remains Beyond Positive Symptoms
Health Medical Acne Aerobics-Cardio Alternative Anti-Aging Build-Muscle Chronic-Illness Dental-Care Depression Diabetes Disability Exercise Eye-Care Fitness-Equipment Hair-Loss Medicine Meditation Nutrition Obesity Polution Quit-Smoking Sidha Supplements Yeast Infection H1N1 Swine Flu SARS herpes therapy panic surgeon hurts teeth remedies eliminate chiropractic arthritis ingredients syndrome binding anxiety surgery medication psychic dental reflux doctor relief premature emotional stress disorder implants wrinkles vision infection aging liposuction seattle stunning sweating hair treatment tinnitus

Pipeline And Commercial Insight: Schizophrenia - Opportunity Remains Beyond Positive Symptoms

Introduction

Introduction

Despite imminent generic erosion of blockbuster brands, the schizophrenia market will retain its value, supported by the uptake of premium priced depot formulations and new pipeline therapies to offset the loss in sales revenue. Datamonitor forecasts the schizophrenia market to grow at a compound annual growth rate of 1.0% (20092019).

Features and benefits

Analysis of current schizophrenia treatment approaches and drug recommendations, patient acquisition process and unmet medical needs.

In depth analysis of historic (200509) and future (20102019) seven major market sales dynamics.

Review of the schizophrenia drug pipeline dynamics, including detailed profiles of key late-stage products.

Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019.

Highlights

Despite the success of the atypical antipsychotics, several major unmet needs remain, including improved patient compliance, solutions for partial responders or treatment refractory patients, improved treatment of cognitive and negative symptoms and therapies with an enhanced side-effect profile.

In the face of increasing cost constraints and competition in the schizophrenia market stemming from the genericization of atypical antipsychotics, Datamonitor does not expect new undifferentiated pipeline products to be positioned as first-line therapies or replicating the success of the current leading atypical antipsychotics.

With current treatment options only exhibiting strong efficacy for positive symptoms, the opportunity remains for developers to address the lucrative patient population suffering from negative and cognitive impairment.

Your key questions answered

Quantify the current and future size of the schizophrenia market.

Identify potential licensing opportunities based on product portfolios and anticipated market needs.

Understand the country-specific impact of key events in the schizophrenia market during the forecast period 2010 to 2019.

For some-more information, Great fully visit:

http://www.aarkstore.com/reports/Pipeline-and-Commercial-Insight-Schizophrenia-Opportunity-remains-beyond-positive-symptoms-80668.html

by: Aarkstore Enterprise
Fat Loss System To Reduce Body Fat Plus Reduce Medical Problems Vitamin E Benefit For Healthy Body Fetal Alcohol Syndrome Symptoms Health Advantages Of Vitamins And Minerals Importance Of Vitamins In Our Body Best Vitamins For Our Body Duraflex Body Kits - Get That Special Look Determining How Much Sleep is Enough for You Best Hemorrhoid Treatment Healthcare Claims Processing – Assuring Accuracy & Profitability Pregnant? baby due in winter,emergency birth, giving birth during a blizzard Hemorrhagic Ovarian Cysts - Causes, Symptoms and Treatment Cheap Metal Detectors Are A Great Way To Make Sure Nobody Gets Shot At Your Party
print
www.yloan.com guest:  register | login | search IP(216.73.216.180) California / Anaheim Processed in 0.016796 second(s), 5 queries , Gzip enabled , discuz 5.5 through PHP 8.3.9 , debug code: 35 , 2418, 61,
Pipeline And Commercial Insight: Schizophrenia - Opportunity Remains Beyond Positive Symptoms Anaheim